Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glucuronosyltransferase | 8 | 2020 | 25 | 3.500 |
Why?
|
| Prostatic Neoplasms | 16 | 2022 | 935 | 1.960 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 312 | 1.130 |
Why?
|
| Receptors, Calcitriol | 2 | 2019 | 69 | 1.050 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 767 | 0.780 |
Why?
|
| DNA Methylation | 1 | 2020 | 325 | 0.580 |
Why?
|
| Polymorphism, Genetic | 3 | 2012 | 191 | 0.550 |
Why?
|
| Logistic Models | 8 | 2019 | 923 | 0.490 |
Why?
|
| Veterans | 4 | 2017 | 122 | 0.470 |
Why?
|
| Glucuronides | 1 | 2012 | 11 | 0.440 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 40 | 0.430 |
Why?
|
| Peritoneal Neoplasms | 1 | 2010 | 16 | 0.360 |
Why?
|
| Middle Aged | 17 | 2019 | 10129 | 0.360 |
Why?
|
| Genetic Variation | 1 | 2012 | 387 | 0.360 |
Why?
|
| Case-Control Studies | 8 | 2017 | 1130 | 0.350 |
Why?
|
| Aged | 15 | 2018 | 6741 | 0.340 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2020 | 11 | 0.310 |
Why?
|
| Humans | 27 | 2022 | 37093 | 0.290 |
Why?
|
| Risk Factors | 10 | 2017 | 3562 | 0.290 |
Why?
|
| Male | 20 | 2022 | 20025 | 0.280 |
Why?
|
| Genetic Association Studies | 2 | 2019 | 114 | 0.280 |
Why?
|
| Body Mass Index | 4 | 2018 | 854 | 0.270 |
Why?
|
| Genotype | 5 | 2012 | 730 | 0.260 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2004 | 11 | 0.240 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2004 | 5 | 0.240 |
Why?
|
| Exercise | 3 | 2018 | 613 | 0.240 |
Why?
|
| Blood | 1 | 2004 | 37 | 0.240 |
Why?
|
| Gene Deletion | 1 | 2004 | 166 | 0.230 |
Why?
|
| Odds Ratio | 5 | 2012 | 534 | 0.230 |
Why?
|
| Isoenzymes | 2 | 2017 | 161 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 515 | 0.200 |
Why?
|
| Bayes Theorem | 1 | 2019 | 94 | 0.160 |
Why?
|
| Retrospective Studies | 5 | 2017 | 2026 | 0.160 |
Why?
|
| Alleles | 2 | 2012 | 321 | 0.150 |
Why?
|
| Dihydrotestosterone | 1 | 2017 | 29 | 0.150 |
Why?
|
| Biopsy | 5 | 2018 | 164 | 0.150 |
Why?
|
| Recurrence | 1 | 2017 | 131 | 0.150 |
Why?
|
| Benzidines | 2 | 2007 | 8 | 0.150 |
Why?
|
| Waist Circumference | 1 | 2017 | 89 | 0.140 |
Why?
|
| Erectile Dysfunction | 1 | 2017 | 38 | 0.140 |
Why?
|
| Vitamin D | 1 | 2019 | 196 | 0.140 |
Why?
|
| Diet | 2 | 2014 | 801 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2007 | 63 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 441 | 0.140 |
Why?
|
| Xenobiotics | 1 | 2015 | 11 | 0.130 |
Why?
|
| Adiposity | 1 | 2017 | 154 | 0.130 |
Why?
|
| Microsomes, Liver | 1 | 2015 | 70 | 0.130 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 893 | 0.130 |
Why?
|
| Dietary Carbohydrates | 1 | 2014 | 31 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 807 | 0.120 |
Why?
|
| Disease Progression | 1 | 2017 | 601 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 974 | 0.120 |
Why?
|
| Female | 6 | 2019 | 20969 | 0.120 |
Why?
|
| North Carolina | 2 | 2014 | 104 | 0.120 |
Why?
|
| Gene Expression | 1 | 2017 | 674 | 0.120 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 85 | 0.120 |
Why?
|
| Alopecia | 1 | 2013 | 9 | 0.110 |
Why?
|
| Homozygote | 1 | 2012 | 77 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 474 | 0.100 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2011 | 9 | 0.100 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 11 | 0.100 |
Why?
|
| Calcium, Dietary | 1 | 2012 | 85 | 0.100 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2011 | 36 | 0.090 |
Why?
|
| Carcinoma | 1 | 2011 | 96 | 0.090 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 485 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 628 | 0.090 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2009 | 9 | 0.090 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2009 | 20 | 0.090 |
Why?
|
| Interleukin-8 | 1 | 2009 | 60 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 2 | 2022 | 118 | 0.080 |
Why?
|
| Psychodrama | 1 | 2009 | 4 | 0.080 |
Why?
|
| Arylamine N-Acetyltransferase | 2 | 2006 | 27 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2018 | 1492 | 0.080 |
Why?
|
| Women's Health | 1 | 2009 | 145 | 0.080 |
Why?
|
| Acetyltransferases | 1 | 2007 | 27 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 97 | 0.070 |
Why?
|
| Base Sequence | 2 | 2004 | 997 | 0.060 |
Why?
|
| Occupational Exposure | 1 | 2006 | 79 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2004 | 4 | 0.060 |
Why?
|
| Pregnancy | 1 | 2010 | 1549 | 0.060 |
Why?
|
| Chromosome Segregation | 1 | 2004 | 41 | 0.060 |
Why?
|
| Gene Frequency | 1 | 2004 | 195 | 0.060 |
Why?
|
| Urine | 1 | 2004 | 13 | 0.060 |
Why?
|
| Endogenous Retroviruses | 1 | 2003 | 16 | 0.060 |
Why?
|
| Enzymes | 1 | 2004 | 32 | 0.060 |
Why?
|
| Meat | 1 | 2004 | 43 | 0.060 |
Why?
|
| Salmonella typhimurium | 1 | 2004 | 40 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2004 | 89 | 0.060 |
Why?
|
| Introns | 1 | 2003 | 75 | 0.060 |
Why?
|
| DNA Primers | 1 | 2004 | 286 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2003 | 66 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2004 | 128 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 59 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 1015 | 0.050 |
Why?
|
| Health Promotion | 1 | 2009 | 653 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2014 | 60 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 864 | 0.050 |
Why?
|
| Adult | 2 | 2010 | 11712 | 0.050 |
Why?
|
| Prostate | 1 | 2022 | 154 | 0.050 |
Why?
|
| Obesity | 2 | 2022 | 1067 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 4268 | 0.040 |
Why?
|
| Incidence | 2 | 2013 | 922 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 1502 | 0.040 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2017 | 14 | 0.040 |
Why?
|
| Acetylation | 2 | 2007 | 98 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2017 | 104 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 583 | 0.030 |
Why?
|
| Benzhydryl Compounds | 1 | 2015 | 43 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2014 | 8 | 0.030 |
Why?
|
| Phenols | 1 | 2015 | 80 | 0.030 |
Why?
|
| United States | 2 | 2017 | 4223 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 267 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1033 | 0.030 |
Why?
|
| Digital Rectal Examination | 1 | 2013 | 4 | 0.030 |
Why?
|
| Age of Onset | 1 | 2013 | 100 | 0.030 |
Why?
|
| Androgens | 1 | 2013 | 89 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2015 | 933 | 0.030 |
Why?
|
| Animals | 4 | 2015 | 15081 | 0.030 |
Why?
|
| Phenotype | 2 | 2006 | 689 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2011 | 149 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2011 | 90 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 1609 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2009 | 2231 | 0.020 |
Why?
|
| Smoking | 1 | 2017 | 940 | 0.020 |
Why?
|
| Mice | 2 | 2015 | 5913 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2009 | 22 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2009 | 27 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 560 | 0.020 |
Why?
|
| Dimerization | 1 | 2009 | 112 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2009 | 54 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 1378 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 131 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 123 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2007 | 41 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 215 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2006 | 30 | 0.020 |
Why?
|
| Cell Line | 1 | 2009 | 1354 | 0.020 |
Why?
|
| China | 1 | 2006 | 196 | 0.020 |
Why?
|
| Health Behavior | 1 | 2009 | 537 | 0.020 |
Why?
|
| Kinetics | 1 | 2006 | 708 | 0.010 |
Why?
|
| Mutagenicity Tests | 1 | 2004 | 21 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2003 | 24 | 0.010 |
Why?
|
| Haptoglobins | 1 | 2003 | 10 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2003 | 32 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2004 | 28 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2003 | 85 | 0.010 |
Why?
|
| Mutagens | 1 | 2004 | 69 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 753 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 295 | 0.010 |
Why?
|
| Cattle | 1 | 2004 | 477 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3483 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 241 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 617 | 0.010 |
Why?
|
| Liver | 1 | 2003 | 479 | 0.010 |
Why?
|